Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRR | Q9GZT4 | 4/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104871 | 0.83 | PPARA (0.47) | PPARGPPARDPPARA | |
| SCHEMBL1368490 | 0.82 | PPARA (0.55) | SRRPPARGPPARDPPARAPSAT1 | |
| SCHEMBL720353 | 0.82 | PPARA (0.55) | SRRPPARGPPARDPPARAPSAT1 | |
| SCHEMBL720354 | 0.82 | PPARA (0.55) | SRRPPARGPPARDPPARAPSAT1 | |
| SCHEMBL1105056 | 0.80 | MAOB (0.46) | SRRMAOBMAOAALDH1A1CYP3A4 | |
| SCHEMBL12581017 | 0.79 | SRR (0.42) | SRRPPARGPPARDPPARAMAOA | |
| SCHEMBL16451001 | 0.77 | ESR1 (0.45) | SRRPPARGPPARDPPARAMAOA | |
| SCHEMBL12665322 | 0.75 | SLC6A4 (0.44) | MAOBMAOAALDH1A1CYP3A4TDP1 | |
| SCHEMBL4085094 | 0.75 | LMNA (0.49) | SRRPPARGPPARDPPARAMAOA | |
| SCHEMBL4085093 | 0.75 | LMNA (0.49) | SRRPPARGPPARDPPARAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10016381-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2018-07-10 | — | — | US | disclosed |
| US-9913817-B2 | Methods for preventing or reducing colon carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2018-03-13 | — | — | US | disclosed |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LTD (IE) | 2018-03-08 | — | — | US | disclosed |
| US-20170312239-A1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2017-11-02 | — | — | US | disclosed |
| US-9682050-B2 | Methods of treating lactose intolerance | NOGRA PHARMA LIMITED (IE) | 2017-06-20 | — | — | US | disclosed |
| US-20170056349-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2017-03-02 | — | — | US | disclosed |
| US-9561202-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2017-02-07 | — | — | US | disclosed |
| US-20150265514-A1 | METHODS OF INHIBITING HAIR GROWTH | NOGRA PHARMA LIMITED (IE) | 2015-09-24 | — | — | US | disclosed |
| US-20150265562-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2015-09-24 | — | — | US | disclosed |
| US-20150250749-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LIMITED (IE) | 2015-09-10 | — | — | US | disclosed |
| US-20150087708-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | disclosed |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | disclosed |
| US-8501806-B2 | Methods for preventing or reducing colon carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2013-08-06 | — | — | US | disclosed |
| US-20130005813-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2013-01-03 | — | — | US | disclosed |
| US-8153841-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-04-10 | — | — | US | disclosed |
| US-20110288177-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2011-11-24 | — | — | US | disclosed |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2011-11-24 | — | — | US | disclosed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | disclosed |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312239-A1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | EGFR, ERBB3, FGFR3 | SRR 1855/4885PPARG 4/4885PPARD 12/4885 |
| US-20170056349-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NQO1, NFE2L2, CYBB | SRR 2309/4885PPARG 806/4885PPARD 1245/4885 |
| US-20150087708-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | SRR 3600/4885PPARG 669/4885PPARD 1293/4885 |
| US-10016381-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | EGFR, ERBB3, FGFR3 | SRR 1855/4885PPARG 4/4885PPARD 12/4885 |
| US-20150265562-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | SRR 1855/4885PPARG 4/4885PPARD 12/4885 |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NQO1, NFE2L2, CYBB | SRR 2309/4885PPARG 806/4885PPARD 1245/4885 |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | SRR 487/4885PPARG 3/4885PPARD 6/4885 |
| US-20150250749-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | EBP, AADAT, ALDH7A1 | SRR 1482/4885PPARG 69/4885PPARD 364/4885 |
| US-20110288177-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | APC, GSTK1, GSTA1 | SRR 2445/4885PPARG 275/4885PPARD 706/4885 |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | EGFR, ERBB3, FGFR3 | SRR 1855/4885PPARG 4/4885PPARD 12/4885 |
| US-20150265514-A1 | METHODS OF INHIBITING HAIR GROWTH | DCX, HDGF, MKI67 | SRR 2022/4885PPARG 3071/4885PPARD 3719/4885 |
| US-20130005813-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | SRR 1855/4885PPARG 4/4885PPARD 12/4885 |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | SRR 487/4885PPARG 3/4885PPARD 6/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | SRR 1693/4885PPARG 1/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.